

ASIAMEDIC LIMITED
(Incorporated in the Republic of Singapore)
Company Registration No.: 197401556E

**PROPOSED RENOUNCEABLE NON-UNDERWRITTEN RIGHTS ISSUE OF UP TO 1,561,952,500
NEW ORDINARY SHARES IN THE CAPITAL OF THE COMPANY**

- RECEIPT OF LISTING AND QUOTATION NOTICE

(A) INTRODUCTION

The Board of Directors (the “**Board**”) of AsiaMedic Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) refers to the Company’s circular to its shareholders dated 14 November 2019 (the “**Circular**”) in relation to, *inter alia*, the Rights Issue.

Unless otherwise defined, capitalised terms herein shall have the same meanings ascribed to them in the Circular.

(B) LISTING AND QUOTATION NOTICE

The Board wishes to announce that the Company had, on 4 December 2019, received the listing and quotation notice from the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) (the “**LQN**”) for the listing and quotation of up to 1,561,952,500 Rights Shares at an issue price of S\$0.012 for each Rights Share.

The Company may proceed with the listing and quotation notice of the Rights Shares, subject to compliance with the SGX-ST’s listing requirements.

The LQN granted by the SGX-ST is not an indication of the merits of the Rights Issue, the Rights Shares, the Company, its subsidiaries and their securities.

(C) OFFER INFORMATION STATEMENT

The Offer Information Statement in relation to, *inter alia*, the Rights Issue will be despatched to Shareholders in due course. Appropriate announcements in relation to the lodgement and despatch of the Offer Information Statement will be made in due course.

(D) TRADING CAUTION

Shareholders and potential investors of the Company are advised to exercise caution when dealing or trading in the securities of the Company. In particular, shareholders and potential investors of the Company should note that the Rights Issue is subject to certain conditions and there is no certainty or assurance as at the date of this announcement that the Rights Issue will be completed or that no changes will be made to the terms and conditions of the Rights Issue. The Company will make further announcements to update its shareholders when there are material updates as may be necessary or appropriate. Shareholders and potential investors of the Company are advised to read this announcement and any further announcements made by the Company carefully. Shareholders and potential investors of the Company should consult their stockbrokers, bank managers, solicitors or other professional advisers if they have any doubt about the actions they should take.

BY ORDER OF THE BOARD

Ms Foo Soon Soo
Company Secretary

5 December 2019

This announcement has been reviewed by the Company's Sponsor, Xandar Capital Pte Ltd, in compliance with Rule 226 of the Rules of Catalist. It has not been examined or approved by the Singapore Exchange Securities Trading Limited ("SGX-ST") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Pauline Sim (Registered Professional, Xandar Capital Pte Ltd) at 3 Shenton Way, #24-02 Shenton House, Singapore 068805. Telephone number: (65) 63194954.